A team of researchers from the University of Oxford and the University of Nottingham have developed \u2018CanPredict\u2019, a new tool able to identify those most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and lives.
Researchers and clinicians in Oxford have begun an evaluation of artificial intelligence (AI) software that could help pathologists diagnose prostate cancer.
Cancer Research UK and the National Institute for Health and Care Research are investing over \u00a33 million across the next five years into The University of Oxford\u2019s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.
IBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.
Dr Bornschein will join the Simmons Group (MRC Human Immunology Unit) for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.
Organised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.
This initiative, announced by the NHS England Chief Executive, is part of the drive to diagnose cancers earlier in the NHS by \u201cfast-tracking\u201d community-based diagnostic testing.
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.
The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive \u00a386.6m over the next five years to fund 15 research themes.
Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.
On Tuesday 13th September, the Oxford early cancer detection community gathered at Worcester College to discuss the latest developments in this field, sparking ideas and collaborations for future research.
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin\u2019s mechanism of action when taken as a preventative for mTP53-driven cancers.
The National Cancer Imaging Translational Accelerator (NCITA) in partnership with the ReIMAGINE Consortium have announced the release of a unique clinical imaging dataset from the Prostate MRI Imaging Study (PROMIS)).
Congratulations to Joshua Bull, Felix Jackson, Eoghan Mulholland and Lauren Murphy who have been awarded OxCODE funds to attend this year\u2019s Early Detection of Cancer conference in Oregon.
Dr Francesco Boccellato wins a CRUK Early Detection and Diagnosis primer award to study tissue shape changes in the pre-cancerous stomach conditions, atrophic gastritis and intestinal metaplasia
The AI-REAL programme led by Professor Anna Schuh and research teams in Tanzania and Uganda is improving the early detection and outcomes of childhood lymphoma in the region by increasing the speed and precision of diagnosis.
![\"Academy](\"https://www.oxcode.ox.ac.uk/news/paresh-vyas-elected-fellow-of-academy-of-medical-sciences/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n